| Name | XST-14 |
| Description | XST-14 is a competitive and specific inhibitor of ULK1 (IC50: 26.6 nM).XST-14 blocks autophagy by inhibiting the phosphorylation of ULK1 downstream substrates.XST-14 induces apoptosis and inhibits the growth of HCC cells. |
| In vitro | Treatment of HepG2 cells with XST-14 (5 μM) alone or in combination with sorafenib (5 μM) for 24 hours showed a synergistic effect, indicating that XST-14 in combination with sorafenib can inhibit HCC in vitro[1]. |
| In vivo | BALB/c mice were treated with XST-14 (30 mg/kg, IP, every other day), sorafenib (30 mg/kg, P.O), or a combination of sorafenib (30 mg/kg, P.O) and XST-14 (30 mg/kg, IP) for 2 weeks. The results indicate that XST-14 exhibits favorable drug metabolism and pharmacokinetic (DMPK) properties, with no significant toxicity observed on liver/kidney function or body weight. |
| Storage | 02 | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (274.59 mM), Sonication is recommended.
|
| Keywords | ULK1 | Autophagy | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Urea | Tamoxifen | Guanidine hydrochloride | Hydroxychloroquine | Metronidazole | Formamide | Paeonol | Naringin | Alginic acid |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Autophagy Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | MAPK Inhibitor Library |
United States
